BCDA — BioCardia, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 925741 ·
Last close
$0.91
Market Cap
$10.36M
52W High
$1.41
52W Low
$0.84
ADV30
262,988
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,266,000 | -2,259,000 | 1,712,000 | 951,000 | 2,778,000 |
| Dec 2025 | 0 | — | -2,013,000 | -1,984,000 | 3,413,000 | 2,496,000 | 2,518,000 |
| Sep 2025 | 0 | — | -1,488,000 | -1,483,000 | 6,148,000 | 5,287,000 | 3,521,000 |
| Jun 2025 | 0 | — | -2,051,000 | -2,049,000 | 2,089,000 | 980,000 | 3,975,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,436,000
Investing CF
$-9,000
Financing CF
$7,568,000
CapEx
$-9,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.84
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-168,349,000
Inventory
—
Receivables
$20,000
ST Investments
—
EBIT TTM
$-8,278,000
Pretax Income TTM
$-8,228,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,278,000 | -8,228,000 | 3,413,000 | 2,518,000 | — | -7,436,000 |
| Dec 2024 | 58,000 | -8,001,000 | -7,946,000 | 3,724,000 | 2,887,000 | — | -7,886,000 |
| Dec 2023 | 477,000 | -11,644,000 | -11,571,000 | 2,987,000 | 4,590,000 | — | -9,974,000 |
| Dec 2022 | 1,352,000 | -11,901,000 | -11,907,000 | 9,793,000 | 4,901,000 | — | -10,561,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CUBT | Curative Biotechnology Inc | $11.49M | $1.50 | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $8.65M | $2.34 | — |
| INTS | INTENSITY THERAPEUTICS, INC. | $12.65M | $4.68 | — |
| PMCB | PharmaCyte Biotech, Inc. | $8.43M | $0.79 | — |
| GNTA | Genenta Science S.p.A. | $14.09M | $0.60 | — |
News headlines (Yahoo Finance, 1h cache)
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
2026-05-21 12:00 · Yahoo
BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
2026-05-19 12:00 · Yahoo
BioCardia (BCDA) Q1 2026 Earnings Transcript
2026-05-18 13:00 · Yahoo
BioCardia, Inc. Q1 2026 Earnings Call Summary
2026-05-16 12:30 · Yahoo
BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ...
2026-05-16 05:00 · Yahoo
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
2026-05-15 12:00 · Yahoo
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
2026-05-11 21:10 · Yahoo
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
2026-05-08 12:00 · Yahoo
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures
2026-04-28 12:00 · Yahoo
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
2026-04-20 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.